MENU
+Compare
PCRX
Stock ticker: NASDAQ
AS OF
Jul 3 closing price
Price
$23.22
Change
+$0.01 (+0.04%)
Capitalization
1.36B

PCRX Pacira BioSciences Forecast, Technical & Fundamental Analysis

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients... Show more

PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PCRX with price predictions
Jul 03, 2025

PCRX sees MACD Histogram crosses below signal line

PCRX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on June 09, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PCRX as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

PCRX moved below its 50-day moving average on June 09, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PCRX crossed bearishly below the 50-day moving average on June 16, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PCRX entered a downward trend on July 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PCRX advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

PCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.557) is normal, around the industry mean (62.462). P/E Ratio (32.742) is within average values for comparable stocks, (88.783). PCRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (2.244) is also within normal values, averaging (19.186).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PCRX is expected to report earnings to rise 10.15% to 68 cents per share on August 05

Pacira BioSciences PCRX Stock Earnings Reports
Q2'25
Est.
$0.68
Q1'25
Beat
by $0.03
Q4'24
Beat
by $0.12
Q3'24
Beat
by $0.09
Q2'24
Beat
by $0.20
The last earnings report on May 08 showed earnings per share of 62 cents, beating the estimate of 58 cents. With 202.32K shares outstanding, the current market capitalization sits at 1.36B.
A.I. Advisor
published General Information

General Information

a manufacturer of injectable therapeutic products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
5401 West Kennedy Boulevard
Phone
+1 813 553-6680
Employees
713
Web
https://www.pacira.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NMANX18.830.26
+1.40%
Neuberger Berman Mid Cap Growth Inv
IMOZX27.590.37
+1.36%
Voya MidCap Opportunities R6
FCALX12.420.14
+1.14%
Fidelity Advisor Climate Action C
PLFMX30.420.25
+0.83%
Principal Large Cap S&P 500 Index R3
FTZCX53.870.32
+0.60%
FullerThaler Behvrll Uncnstd Eq C

PCRX and Stocks

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
+0.04%
ELAN - PCRX
31%
Poorly correlated
-0.54%
TEVA - PCRX
29%
Poorly correlated
-0.23%
NBIX - PCRX
25%
Poorly correlated
-0.22%
ALKS - PCRX
24%
Poorly correlated
-0.52%
ESPR - PCRX
23%
Poorly correlated
+1.74%
More